What is the recommended dosing of Valtrex (valacyclovir) for a pregnant woman in her 3rd trimester with a history of herpes simplex virus (HSV) infection?

Valtrex Dosing in Third Trimester

For pregnant women with recurrent genital herpes in the third trimester, initiate suppressive therapy with valacyclovir 500 mg orally twice daily starting at 36 weeks gestation and continuing until delivery to reduce HSV recurrences and cesarean delivery rates. 1, 2

Clinical Context and Rationale

The primary goal of antiviral suppression in late pregnancy is to reduce viral shedding at delivery and prevent the need for cesarean delivery due to active lesions, which directly impacts maternal morbidity and neonatal HSV transmission risk. 1, 2

• Neonatal transmission risk is highest (30-50%) when primary HSV infection occurs near delivery, but only 1-3% with recurrent HSV at term. 1, 3
• Most cases of neonatal herpes occur in mothers without known history of genital herpes, making suppression in known cases particularly important. 4

Specific Dosing Recommendations

For Suppressive Prophylaxis (Starting at 36 Weeks)

• Valacyclovir 500 mg orally twice daily from 36 weeks until delivery 1, 2
• Alternative: Acyclovir 400 mg orally three times daily 1
• This regimen reduces clinical HSV recurrences from 27% to 10.5% and HSV detection at delivery from 13% to 4%. 5, 2

For Acute Recurrent Episodes During Pregnancy

• Valacyclovir 500 mg orally twice daily for 3-5 days 6, 4
• Alternative: Acyclovir 200 mg orally five times daily for 5 days 4

For First Episode Genital Herpes During Pregnancy

• Valacyclovir 1 gram orally twice daily for 7-10 days 6, 1
• Alternative: Acyclovir 400 mg orally three times daily for 7-10 days 6, 1
• Initiate treatment within 48 hours of symptom onset for maximum efficacy. 1

Critical Safety Information

Valacyclovir and acyclovir are safe throughout pregnancy, with no increased risk of major birth defects compared to the general population. 3

• Registry data from over 1,200 pregnancies show birth defect rates of 2.6-3.9%, consistent with background population risk of 2-4%. 3
• Pharmacokinetic studies demonstrate no preferential fetal accumulation, with maternal/fetal plasma ratios of 1.3-1.7. 7, 8
• No maternal or neonatal toxicity has been identified in clinical trials. 5, 7, 2

Important Caveats and Clinical Pitfalls

Acyclovir is preferred over valacyclovir for life-threatening maternal HSV infections (disseminated infection, encephalitis, pneumonitis, hepatitis). 9

• Use intravenous acyclovir 5 mg/kg every 8 hours for severe maternal disease. 6, 1

Do not use routine suppressive therapy before 36 weeks gestation in women without active recurrences. 1

• Suppressive therapy is specifically indicated starting at 36 weeks to reduce peripartum transmission risk. 1, 2

Cesarean delivery is indicated if visible genital lesions or prodromal symptoms are present at labor onset, regardless of suppressive therapy. 1

• Suppressive therapy reduces but does not eliminate the need for cesarean delivery in women with active lesions at term. 2

Special Populations

HIV-Infected Pregnant Women

• Same valacyclovir dosing applies (500 mg twice daily from 36 weeks). 1
• Some experts recommend prophylaxis for those with frequent, severe recurrences even earlier in pregnancy. 6

Immunocompromised Patients

• May require higher doses: acyclovir 400 mg orally three to five times daily. 9, 6
• If lesions persist during standard treatment, suspect acyclovir resistance and consider alternative therapy. 9

Delivery Management Algorithm

1. No visible lesions or prodromal symptoms at labor onset: Proceed with vaginal delivery 1
2. Visible lesions or prodromal symptoms present: Cesarean delivery recommended 1
3. First episode within 6 weeks of delivery: Cesarean delivery recommended 4
4. Recurrent episode with prolonged rupture of membranes: Consider vaginal delivery 4

Neonatal Follow-Up

All infants exposed to HSV during delivery require careful monitoring with viral cultures of mucosal surfaces obtained 24-48 hours after birth. 1

• Treatment with intravenous acyclovir should be reserved only for infants who develop clinical disease or have positive cultures. 6, 1
• Do not routinely treat asymptomatic exposed infants. 6